Cargando…

Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus

AIM: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of a novel, oral glucagon receptor antagonist, LGD‐6972, in healthy subjects and subjects with type 2 diabetes (T2DM). METHODS: In the single ascending dose study, LGD‐6972 (2‐480 mg) was ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Vajda, Eric G., Logan, Douglas, Lasseter, Kenneth, Armas, Danielle, Plotkin, Diane J., Pipkin, JD, Li, Yong-Xi, Zhou, Rong, Klein, David, Wei, Xiaoxiong, Dilzer, Stacy, Zhi, Lin, Marschke, Keith B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215471/
https://www.ncbi.nlm.nih.gov/pubmed/27501510
http://dx.doi.org/10.1111/dom.12752
_version_ 1782491766408085504
author Vajda, Eric G.
Logan, Douglas
Lasseter, Kenneth
Armas, Danielle
Plotkin, Diane J.
Pipkin, JD
Li, Yong-Xi
Zhou, Rong
Klein, David
Wei, Xiaoxiong
Dilzer, Stacy
Zhi, Lin
Marschke, Keith B.
author_facet Vajda, Eric G.
Logan, Douglas
Lasseter, Kenneth
Armas, Danielle
Plotkin, Diane J.
Pipkin, JD
Li, Yong-Xi
Zhou, Rong
Klein, David
Wei, Xiaoxiong
Dilzer, Stacy
Zhi, Lin
Marschke, Keith B.
author_sort Vajda, Eric G.
collection PubMed
description AIM: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of a novel, oral glucagon receptor antagonist, LGD‐6972, in healthy subjects and subjects with type 2 diabetes (T2DM). METHODS: In the single ascending dose study, LGD‐6972 (2‐480 mg) was administered to healthy subjects (n = 48) and T2DM subjects (n = 8). In the multiple ascending dose study, healthy subjects (n = 12) received a dose of 15 mg LGD‐6972 and T2DM subjects (n = 36) received doses of 5, 10 or 15 mg of LGD‐6972 daily for 14 days. RESULTS: LGD‐6972 had linear plasma pharmacokinetics consistent with once‐daily dosing that was comparable in healthy and T2DM subjects. Dose‐dependent decreases in fasting plasma glucose were observed in all groups with a maximum of 3.15 mmol/L (56.8 mg/dL) on day 14 in T2DM subjects. LGD‐6972 also reduced plasma glucose in the postprandial state. Dose‐dependent increases in fasting plasma glucagon were observed, but glucagon levels decreased and insulin levels increased after an oral glucose load in T2DM subjects. LGD‐6972 was well tolerated at the doses tested without dose‐related or clinically meaningful changes in clinical laboratory parameters. No subject experienced hypoglycaemia. CONCLUSION: Inhibition of glucagon action by LGD‐6972 was associated with decreases in glucose in both healthy and T2DM subjects, the magnitude of which was sufficient to predict improvement in glycaemic control with longer treatment duration in T2DM patients. The safety and pharmacological profile of LGD‐6972 after 14 days of dosing supports continued clinical development.
format Online
Article
Text
id pubmed-5215471
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-52154712017-01-18 Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus Vajda, Eric G. Logan, Douglas Lasseter, Kenneth Armas, Danielle Plotkin, Diane J. Pipkin, JD Li, Yong-Xi Zhou, Rong Klein, David Wei, Xiaoxiong Dilzer, Stacy Zhi, Lin Marschke, Keith B. Diabetes Obes Metab Original Articles AIM: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of a novel, oral glucagon receptor antagonist, LGD‐6972, in healthy subjects and subjects with type 2 diabetes (T2DM). METHODS: In the single ascending dose study, LGD‐6972 (2‐480 mg) was administered to healthy subjects (n = 48) and T2DM subjects (n = 8). In the multiple ascending dose study, healthy subjects (n = 12) received a dose of 15 mg LGD‐6972 and T2DM subjects (n = 36) received doses of 5, 10 or 15 mg of LGD‐6972 daily for 14 days. RESULTS: LGD‐6972 had linear plasma pharmacokinetics consistent with once‐daily dosing that was comparable in healthy and T2DM subjects. Dose‐dependent decreases in fasting plasma glucose were observed in all groups with a maximum of 3.15 mmol/L (56.8 mg/dL) on day 14 in T2DM subjects. LGD‐6972 also reduced plasma glucose in the postprandial state. Dose‐dependent increases in fasting plasma glucagon were observed, but glucagon levels decreased and insulin levels increased after an oral glucose load in T2DM subjects. LGD‐6972 was well tolerated at the doses tested without dose‐related or clinically meaningful changes in clinical laboratory parameters. No subject experienced hypoglycaemia. CONCLUSION: Inhibition of glucagon action by LGD‐6972 was associated with decreases in glucose in both healthy and T2DM subjects, the magnitude of which was sufficient to predict improvement in glycaemic control with longer treatment duration in T2DM patients. The safety and pharmacological profile of LGD‐6972 after 14 days of dosing supports continued clinical development. Blackwell Publishing Ltd 2016-08-31 2017-01 /pmc/articles/PMC5215471/ /pubmed/27501510 http://dx.doi.org/10.1111/dom.12752 Text en © 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Vajda, Eric G.
Logan, Douglas
Lasseter, Kenneth
Armas, Danielle
Plotkin, Diane J.
Pipkin, JD
Li, Yong-Xi
Zhou, Rong
Klein, David
Wei, Xiaoxiong
Dilzer, Stacy
Zhi, Lin
Marschke, Keith B.
Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus
title Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus
title_full Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus
title_fullStr Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus
title_full_unstemmed Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus
title_short Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD‐6972 in healthy subjects and subjects with type 2 diabetes mellitus
title_sort pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist lgd‐6972 in healthy subjects and subjects with type 2 diabetes mellitus
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215471/
https://www.ncbi.nlm.nih.gov/pubmed/27501510
http://dx.doi.org/10.1111/dom.12752
work_keys_str_mv AT vajdaericg pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT logandouglas pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT lasseterkenneth pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT armasdanielle pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT plotkindianej pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT pipkinjd pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT liyongxi pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT zhourong pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT kleindavid pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT weixiaoxiong pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT dilzerstacy pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT zhilin pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus
AT marschkekeithb pharmacokineticsandpharmacodynamicsofsingleandmultipledosesoftheglucagonreceptorantagonistlgd6972inhealthysubjectsandsubjectswithtype2diabetesmellitus